
Monogram Orthopedics
Monogram Orthopedics | Online Public Offering.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 Valuation: €0.0 | round | |
N/A | €0.0 | round | |
* | N/A | $13.0m | Post IPO Convertible |
Total Funding | 000k |
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | - | - | (1577 %) | - | (5464 %) | - | - |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | - | - | (1881 %) | - | (3766 %) | - | - |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | - | - | 840 % | - | 2900 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Monogram Orthopaedics Inc. (NASDAQ: MGRM) is a medical technology company based in Austin, TX, specializing in reconstructive joint procedures and surgical robotics. The company focuses on developing advanced robotic systems to improve the precision and outcomes of joint surgeries. Monogram serves healthcare providers, including hospitals and surgical centers, by offering cutting-edge robotic solutions that enhance surgical accuracy and efficiency. Operating in the medical technology market, Monogram's business model revolves around the development, commercialization, and sale of its proprietary surgical robots. The company generates revenue through the sale of these robots and related services. Recently, Monogram achieved a significant milestone by delivering its first surgical robot to a major global distributor, marking the start of its commercial revenue stream. The company is currently in the Verification Phase of its next-generation autonomous surgical robotic system, which involves extensive testing to ensure optimal performance. With a cash runway of approximately 15 months as of September 2023, Monogram is strategically positioned to advance its technology and expand its market presence.
Keywords: surgical robotics, reconstructive joint procedures, medical technology, healthcare providers, robotic systems, surgical accuracy, commercialization, revenue generation, autonomous robots, market expansion.